GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Compound class:
Synthetic organic
Comment: TNG260 is an HDAC1 inhibitor with activity at the HDAC1/LSD1/RCOR1 (REST corepressor 1) complex. The compound reverses anti-PD1 resistance (immune evasion phenotype) that is driven by loss-of-function mutations in serine/threonine kinase 11 (STK11; LKB1). TNG260 is designed for potential to treat STK11 mutant cancers in combination with checkpoint inhibition. The chemical structure was disclosed during the 'First Disclosures of New Drug Candidates' session at the April 2023 (Orlando) meeting of the AACR.
|
|
Bioactivity Comments |
TNG260 induces tumour regressions in an STK11-mutant model in combination with anti-PD-1 treatment. |